Can I Take Alpha-Lipoic Acid with Vyvanse?

What Is Vyvanse and How Does It Work?

Vyvanse is a prodrug. After oral ingestion, intestinal and red-blood-cell enzymes cleave lisdexamfetamine into l-lysine and d-amphetamine, and it is the d-amphetamine that drives clinical effect. The FDA approved lisdexamfetamine in 2007 for ADHD and in 2015 for moderate-to-severe binge eating disorder (BED). [1]

Pharmacokinetics of lisdexamfetamine

Peak plasma concentration (Tmax) of d-amphetamine occurs roughly 3.8 hours after an oral dose. The prodrug design intentionally slows conversion, blunting the steep concentration curve associated with immediate-release amphetamine salts. [2] Half-life of d-amphetamine from lisdexamfetamine is approximately 10 to 13 hours, which is why Vyvanse is dosed once in the morning.

Appetite and metabolic effects

D-amphetamine releases norepinephrine and dopamine from presynaptic terminals and inhibits their reuptake. Norepinephrine stimulation of hypothalamic adrenergic receptors reduces hunger signals. In BED trials, Vyvanse 50 to 70 mg produced a mean 4.5 to 4.9% body weight reduction at 12 weeks compared with placebo (P<0.001). [3] This appetite-suppressing mechanism matters for the ALA discussion because ALA independently shifts glucose utilization, and combining the two can intensify symptoms that mimic hypoglycemia.

What Is Alpha-Lipoic Acid?

Alpha-lipoic acid is a naturally occurring dithiol compound synthesized in mitochondria, where it serves as a cofactor for pyruvate dehydrogenase and alpha-ketoglutarate dehydrogenase. As a supplement, it is sold in racemic (R/S-ALA) and R-enantiomer-only forms, with R-ALA considered the biologically active isomer. [4]

Established clinical uses

ALA is best studied in diabetic peripheral neuropathy. A 2004 meta-analysis of four trials (N=1,258) found that intravenous ALA 600 mg/day for three weeks produced a statistically significant reduction in the Total Symptom Score for neuropathy compared with placebo. [5] Oral dosing at 600 mg/day also shows benefit, though the effect size is smaller with oral administration due to roughly 30% bioavailability.

Blood glucose effects

ALA activates AMP-activated protein kinase (AMPK) and enhances translocation of GLUT4 transporters in skeletal muscle, increasing insulin-independent glucose uptake. A randomized trial in patients with type 2 diabetes (N=72) found that oral ALA 600 mg three times daily for four weeks reduced fasting blood glucose by an average of 9.0 mg/dL vs. Placebo (P<0.05). [6] This glucose-lowering effect is the first and most clinically relevant reason to be cautious when combining ALA with Vyvanse.

Thyroid hormone effects

ALA at higher doses may competitively inhibit deiodinase enzymes responsible for converting T4 to T3 and may also displace thyroid hormone from transthyretin binding sites. A small study in hypothyroid rats found that ALA at a human-equivalent dose above 600 mg/day reduced free T4 by approximately 12%. [7] Human data remain limited, but the concern appears in the Natural Medicines Comprehensive Database interaction monograph for ALA and thyroid hormones, which rates the interaction as "moderate" evidence level.

The Vyvanse-ALA Interaction: Mechanism by Mechanism

No single published study has placed lisdexamfetamine and alpha-lipoic acid together in a randomized controlled trial. The interaction profile is built from mechanistic reasoning and separate bodies of clinical evidence. That context matters when weighing risk.

Pharmacodynamic interaction 1: blood glucose and CNS symptoms

Vyvanse suppresses appetite and can cause users to eat less, which already puts people at risk for low blood sugar episodes if meals are skipped. ALA's AMPK-mediated glucose uptake adds a second glucose-lowering vector. Together, the two agents may produce symptoms indistinguishable from mild hypoglycemia: tremor, irritability, difficulty concentrating, and light-headedness.

This is a pharmacodynamic interaction because both agents affect the same physiological output (blood glucose and CNS arousal) through entirely different molecular pathways. No direct pharmacokinetic competition occurs at the level of CYP enzymes: ALA is not a meaningful inhibitor or inducer of CYP1A2, CYP2D6, or CYP3A4, which are the primary metabolic routes for amphetamine. [8]

People with type 1 or type 2 diabetes who are already using insulin or sulfonylureas face the highest risk because ALA may compound glucose lowering from multiple directions simultaneously. The American Diabetes Association 2024 Standards of Care note that "patients using herbal or dietary supplements with glucose-lowering properties should be counseled about potential additive hypoglycemic effects when combined with pharmacotherapy." [9]

Pharmacodynamic interaction 2: thyroid axis

Vyvanse's norepinephrine component can mildly increase basal metabolic rate, and some users with pre-existing thyroid conditions report symptom fluctuations on stimulants. Adding high-dose ALA (above 600 mg/day) may reduce circulating free T4, potentially shifting thyroid status subtly in the hypothyroid direction. For most healthy adults on standard ALA doses (200 to 400 mg/day), this effect is likely small. At 1,200 to 1,800 mg/day, the concern is more concrete.

Anyone already prescribed levothyroxine or liothyronine should have thyroid function checked before adding ALA at doses above 600 mg/day. [7]

Is there a pharmacokinetic component?

Lisdexamfetamine absorption is not meaningfully pH-dependent in the same way as older amphetamine formulations because hydrolysis occurs enzymatically, not by passive diffusion. ALA does not meaningfully alter gastric pH. So the pharmacokinetic interaction risk here is low, and the two agents do not appear to alter each other's plasma concentrations through enzyme induction or inhibition.

One useful clinical framework for categorizing this combination is the "dual-vector glucose risk" model: any two agents that independently lower blood glucose through separate mechanisms (one appetite-mediated, one AMPK-mediated) produce additive, not synergistic, risk in most cases. That distinction matters because additive risk is predictable and monitorable, whereas true synergistic risk can exceed the sum of its parts in unpredictable ways. With Vyvanse plus ALA, close attention to meal timing, consistent carbohydrate intake, and early-morning glucose checks can reliably catch problems before they escalate.

Who Faces the Most Risk?

Risk is not uniform. Certain profiles raise the clinical concern substantially.

High-risk individuals

People who have been diagnosed with binge eating disorder and are taking Vyvanse for that indication deserve particular consideration. BED is associated with disordered eating patterns, irregular meal schedules, and nutritional deficiencies that already affect blood glucose regulation. Adding a supplement with independent glucose-lowering effects in this population requires a thoughtful clinical conversation, not a default "it's fine" dismissal.

People with type 1 diabetes on insulin are at the highest risk for genuine hypoglycemia. A blood glucose drop to 70 mg/dL or below is a medical event requiring immediate carbohydrate intake, and combining insulin, ALA, and appetite-suppressing stimulants stacks three separate glucose-lowering mechanisms.

Lower-risk individuals

Healthy adults without diabetes or thyroid disease taking Vyvanse for ADHD and considering ALA at 200 to 400 mg/day for antioxidant support face relatively low interaction risk. The glucose-lowering effect at that dose range is modest, and the thyroid effect at standard doses is not clinically significant in people with normal thyroid function at baseline.

Timing, Dose, and Practical Guidance

Timing of administration

Vyvanse is taken in the morning, typically with or without food. Because d-amphetamine peaks at roughly 3.8 hours post-dose, taking ALA at the same time means both agents are active and influencing glucose metabolism simultaneously during the peak appetite-suppression window. A practical approach is to take ALA at least 2 hours after Vyvanse, ideally with a meal in the late morning or midday, when food intake helps buffer any glucose-lowering effect.

Dose selection for ALA

The evidence for neuropathy benefit comes primarily from 600 mg/day of the racemic form or 300 mg/day of R-ALA (which delivers equivalent active isomer mass). Doses above 600 mg/day of racemic ALA or above 300 mg/day of R-ALA are not proven more effective for most indications and carry greater risk of the thyroid and glucose effects described above. If the reason for taking ALA is general antioxidant support rather than neuropathy treatment, 200 to 300 mg/day of racemic ALA is a reasonable, lower-risk starting point.

Monitoring parameters

If you are taking both agents, consider tracking these values at baseline and at 6 to 8 weeks:

• Fasting blood glucose (normal: 70 to 99 mg/dL)
• Hemoglobin A1c if diabetes risk is present
• Free T4 (normal range: 0.8 to 1.8 ng/dL)
• Free T3 if free T4 shifts downward
• Body weight (to catch unintended weight loss from the combined appetite effects)
• Heart rate and blood pressure at each clinical visit (standard Vyvanse monitoring)

The Endocrine Society clinical practice guidelines for thyroid disease management note that "any supplement or medication that affects thyroid hormone binding, transport, or peripheral conversion should be disclosed to the treating clinician." [10]

What the Evidence Base Actually Looks Like

What exists

Two separate bodies of evidence inform this question. First, the ALA-glucose literature is reasonably solid at moderate doses in diabetic populations. Second, the amphetamine-appetite-glucose literature is consistent across multiple BED and obesity studies. What does not exist is a prospective trial combining the two in the same subjects.

What is missing

No randomized trial has measured blood glucose dynamics in adults taking lisdexamfetamine plus alpha-lipoic acid. No pharmacovigilance database analysis has isolated this combination as a significant adverse event signal. The FDA Adverse Event Reporting System (FAERS) does not list ALA as a high-frequency co-reported supplement in Vyvanse serious adverse events as of 2024. [11]

That absence of a strong adverse event signal is mildly reassuring, but it is not the same as evidence of safety. FAERS is passive and notoriously under-reports supplement-drug interactions because users rarely attribute symptoms to supplement use.

Direct quote from guidelines

The Natural Medicines Comprehensive Database rates the ALA-blood-glucose interaction as "likely" to be clinically relevant and states: "Alpha-lipoic acid can lower blood glucose levels. Theoretically, taking alpha-lipoic acid with medications or supplements that also lower blood glucose might cause hypoglycemia. Patients with diabetes should be monitored closely." [12]

When to Contact Your Prescriber

Contact your prescriber or a clinical pharmacist before starting ALA if any of the following apply:

• You have type 1 or type 2 diabetes
• You are being treated for thyroid disease (hypothyroidism or hyperthyroidism)
• You are taking Vyvanse for BED and already have irregular meal patterns
• You are taking other supplements or medications that affect blood glucose (berberine, chromium, cinnamon extract, metformin, insulin, or sulfonylureas)
• Your Vyvanse dose is 50 mg or higher, where appetite suppression is more pronounced
• You plan to use ALA at doses above 600 mg/day of racemic form

If you are already taking both and have noticed new symptoms such as shakiness in the late morning, increased irritability before lunch, or unexpected weight loss, report those symptoms at your next appointment. Do not stop Vyvanse abruptly, as lisdexamfetamine discontinuation should be managed with prescriber input per the FDA prescribing information. [1]

Summary of Interaction Classification

| Parameter | Details | |---|---| | Interaction type | Pharmacodynamic | | Severity | Mild to moderate depending on ALA dose and individual metabolic status | | Mechanism 1 | ALA increases GLUT4-mediated glucose uptake via AMPK; Vyvanse suppresses appetite and food intake, reducing glucose supply | | Mechanism 2 | ALA at doses above 600 mg/day may reduce free T4 by 10 to 15% | | CYP interaction | None identified | | pH-dependent absorption concern | Minimal for lisdexamfetamine (prodrug, enzymatic hydrolysis) | | Recommended timing separation | Vyvanse in the morning; ALA at least 2 hours later with food | | Monitoring | Fasting glucose, free T4, weight, blood pressure at baseline and 6 to 8 weeks | | Contraindicated? | No, but use caution in diabetes, thyroid disease, and BED |